These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 18186971)

  • 1. Is NICE infallible? A qualitative study of its assessment of treatments for attention-deficit/hyperactivity disorder (ADHD).
    Schlander M
    Curr Med Res Opin; 2008 Feb; 24(2):515-35. PubMed ID: 18186971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Has NICE got it right? An international perspective considering the case of Technology Appraisal No. 98 by the National Institute for Health and Clinical Excellence (NICE).
    Schlander M
    Curr Med Res Opin; 2008 Apr; 24(4):951-66. PubMed ID: 18279581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents.
    King S; Griffin S; Hodges Z; Weatherly H; Asseburg C; Richardson G; Golder S; Taylor E; Drummond M; Riemsma R
    Health Technol Assess; 2006 Jul; 10(23):iii-iv, xiii-146. PubMed ID: 16796929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methodological issues in undertaking independent cost-effectiveness analysis for NICE: the case of therapies for ADHD.
    Griffin SC; Weatherly HL; Richardson GA; Drummond MF
    Eur J Health Econ; 2008 May; 9(2):137-45. PubMed ID: 17476538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom.
    Cottrell S; Tilden D; Robinson P; Bae J; Arellano J; Edgell E; Aristides M; Boye KS
    Value Health; 2008; 11(3):376-88. PubMed ID: 18489664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NICE accountability for reasonableness: a qualitative study of its appraisal of treatments for attention-deficit/hyperactivity disorder (ADHD).
    Schlander M
    Curr Med Res Opin; 2007 Jan; 23(1):207-22. PubMed ID: 17261237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the value of atomoxetine in treating children and adolescents with ADHD in the UK.
    Prasad S; Arellano J; Steer C; Libretto SE
    Int J Clin Pract; 2009 Jul; 63(7):1031-40. PubMed ID: 19570121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The NICE ADHD health technology assessment: a review and critique.
    Schlander M
    Child Adolesc Psychiatry Ment Health; 2008 Jan; 2(1):1. PubMed ID: 18197978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-acting medications for the hyperkinetic disorders. A note on cost-effectiveness.
    Schlander M
    Eur Child Adolesc Psychiatry; 2007 Oct; 16(7):421-9. PubMed ID: 17401606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine.
    Roskell NS; Setyawan J; Zimovetz EA; Hodgkins P
    Curr Med Res Opin; 2014 Aug; 30(8):1673-85. PubMed ID: 24627974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion.
    Stuhec M; Munda B; Svab V; Locatelli I
    J Affect Disord; 2015 Jun; 178():149-59. PubMed ID: 25813457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Appraisals by Health Technology Assessment Agencies of Economic Evaluations Submitted as Part of Reimbursement Dossiers for Oncology Treatments: Evidence from Canada, the UK, and Australia.
    Ball G; Levine MAH; Thabane L; Tarride JE
    Curr Oncol; 2022 Oct; 29(10):7624-7636. PubMed ID: 36290879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY)--a pharmacoepidemiological and qualitative study.
    Wong IC; Asherson P; Bilbow A; Clifford S; Coghill D; DeSoysa R; Hollis C; McCarthy S; Murray M; Planner C; Potts L; Sayal K; Taylor E
    Health Technol Assess; 2009 Oct; 13(50):iii-iv, ix-xi, 1-120. PubMed ID: 19883527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development.
    Claxton K; Palmer S; Longworth L; Bojke L; Griffin S; McKenna C; Soares M; Spackman E; Youn J
    Health Technol Assess; 2012; 16(46):1-323. PubMed ID: 23177626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Methylphenidate in the treatment of attention-deficit/hyperactivity disorder: are we achieving an adequate clinical practice?].
    Gonzalez de Dios J; Cardó E; Servera M
    Rev Neurol; 2006 Dec 16-31; 43(12):705-14. PubMed ID: 17160919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: qualitative synthesis of scientific evidence.
    Catalá-López F; Ridao M; Sanfélix-Gimeno G; Peiró S
    Rev Psiquiatr Salud Ment; 2013; 6(4):168-77. PubMed ID: 23453596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of attention-deficit/hyperactivity disorder: overview of the evidence.
    Brown RT; Amler RW; Freeman WS; Perrin JM; Stein MT; Feldman HM; Pierce K; Wolraich ML; ;
    Pediatrics; 2005 Jun; 115(6):e749-57. PubMed ID: 15930203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medication options when treating children and adolescents with ADHD: interpreting the NICE guidance 2006.
    Harpin VA
    Arch Dis Child Educ Pract Ed; 2008 Apr; 93(2):58-65. PubMed ID: 18356307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review of economic evaluations in second and later lines of therapy for the treatment of non-small cell lung cancer.
    Jäkel A; Plested M; Dharamshi K; Modha R; Bridge S; Johns A
    Appl Health Econ Health Policy; 2013 Feb; 11(1):27-43. PubMed ID: 23329379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current and Investigational Medication Delivery Systems for Treating Attention-Deficit/Hyperactivity Disorder.
    Jain R; Katic A
    Prim Care Companion CNS Disord; 2016 Aug; 18(4):. PubMed ID: 27828696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.